NSNikita A. Savelov

Nikita A. Savelov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikita A. Savelov has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessment methodology of pathomorphological regression of melanoma metastasis in the sentinel lymph node after neoadjuvant/perioperative immunotherapy

    by L.V. Moskvina, G.A. Raskin, N.A. Savelov, Ya.V. Vishnevskaya, L.E. Zavalishina, D.O. Zagvozkina, A.G. Kudaibergenova, D.A. Tsekatunov, O.YU. Chukhray, A.YU. Shamanova, et al.

    This methodology has been developed to standardize the pathology evaluation of melanoma metastasis regression in the sentinel lymph node after neoadjuvant/perioperative immunotherapy in patients with stage III resectable cutaneous melanoma. The methodology is intended for use by pathologists, clinical and surgical oncologists, and healthcare quality assessment experts. It can be implemented as a local protocol for pathological examination, as well as integrated into national clinical guidelines and relevant organizational and methodological documents.

  • Quality control of immunohistochemical studies in Russia in 2025: achievement and prospects

    by L.E. Zavalishina, S.V. Vtorushin, G.A. Raskin, S.V. Petrov, Yu.YU. Andreeva, A.A. Barinov, I.YU. Vinogradov, I.A. Demidova, O.A. Kuznetsova, E.M. Olyushina, et al.

    Immunohistochemistry is one of the key methods of modern morphological diagnostics, providing both differential diagnosis of neoplastic and non-neoplastic processes and the assessment of prognostic and predictive biomarkers relevant for the selection of drug therapy. The multistep nature of immunohistochemical studies is associated with a high risk of methodological errors at the preanalytical, analytical, and postanalytical stages, which may lead to reduced reproducibility of results and the development of clinically significant diagnostic inaccuracies. Objective. To assess the quality of immunohistochemical studies at all stages of the laboratory workflow in medical institutions participating in the external quality assessment program of the Immunohistochemistry Quality Control Center of the Russian Medical Academy of Continuous Professional Education in 2025. Material and methods. The results of 18 external quality assessment rounds covering the preanalytical, analytical, and postanalytical stages of immunohistochemical studies were analyzed. Expert evaluation was performed by the Expert Council of the Immunohistochemistry Quality Control Center in accordance with approved assessment criteria and current clinical guidelines. Results. At the preanalytical stage, typical violations related to fixation and histological processing of biological material were identified, significantly affecting the quality of immunohistochemical and molecular genetic studies. At the analytical stage, the main causes of unsatisfactory results were insufficient intralaboratory validation of protocols, the use of non-recommended antibody clones, and the absence of adequate control samples. At the postanalytical stage, errors in result interpretation not compliant with current clinical guideline requirements were detected. Laboratories that repeatedly participated in external quality assessment rounds demonstrated a statistically significant improvement in results following the implementation of individualized expert recommendations. Conclusion. External quality assessment of immunohistochemical studies is an effective tool for improving the reproducibility and clinical relevance of morphological research results. Regular participation of laboratories in quality control programs, standardization of methodological approaches, and systematic professional training of specialists contribute to a reduction in diagnostic errors and to improving the quality of morphological diagnostics and personalized patient management.

  • Open Access

    Intraductal papillary mucinous neoplasms of the pancreas associated with ductal carcinoma as two distinct clinical entities

    by O. V. Paklina, K. K. Noskova, I. S. Abramov, N. A. Bodunova, N. A. Savelov

    Aim. To analyze current perspectives on the concept of malignant progression in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and to outline the most prospective research trends in this area.Materials and Methods. A literature review and an analysis of data from the cancer registry of Moscow were conducted. Results. The paper summarizes key molecular genetic studies from recent decades. Using surgical specimen data coded according to ICD-O in Moscow for the years 2023–2024, the main challenges in the histopathological diagnosis of IPMN with associated invasive carcinoma are discussed.Conclusion. Genomic alterations in IPMNs of the pancreas, as background lesions for pancreatic ductal adenocarcinoma, reflect their genetic heterogeneity and carry significant clinical implications for understanding the polyclonal theory of carcinogenesis, as well as for identifying novel therapeutic targets and approaches. The invasive component associated with IPMN is frequently genetically independent based on its molecular profile.

  • Solitary fibrous tumor of common bile duct: case report and literature review

    by D.E. Suraev, M.V. Moskalets, S.A. Sokolov, A.A. Chankina, N.A. Savelov, D.YU. Kanner, O.V. Paklina

    Solitary fibrous tumor (SFT) is a rare mesenchymal tumor. SFT was first described by Klemperer and Rabin in 1931. They described a fibrous tumor of the pleura. Currently, isolated cases of SFT of the gallbladder and common bile duct have been described in the world. SFT is characterized by nuclear expression of STAT6 and the formation of chimeric genes NAB2-STAT6. A case report of a rare SFT of the common bile duct in a 66-year-old patient is presented. The description contains data from radiation and ultrasound diagnostic methods, macro- and microscopic characteristics of the tumor and immunohistochemical characteristics.


  • Quality control of immunohistochemical studies: compulsory duty or urgent need?

    by L.E. Zavalishina, Yu.YU. Andreeva, A.A. Barinov, I.YU. Vinogradov, S.V. Vtorushin, I.A. Demidova, O.A. Kuznetsova, E.M. Olyushina, S.V. Petrov, G.A. Raskin, et al.

    Immunohistochemical study is an integral component of modern morphologic diagnostics, providing accurate marker detection and identification of molecular subtypes of malignant neoplasms. A quality control system is fundamental in the aspect of standardizing laboratory protocols, ensuring reproducibility of results and increasing the reliability of diagnostic conclusions. Objective. To conduct a comprehensive assessment of the quality of immunohistochemical studies at the successive stages of the laboratory process (pre-analytical, analytical, post-analytical) in medical organizations that are participants of the external quality control program of the IHC Quality Control Center of Russian Medical Academy of Continuous Professional Education for 2024. Material and Methods. The present study analyzed the results of external quality control rounds initiated by the Quality Control Center. The nature and frequency of errors at all stages of immunohistochemical study, including procedures for fixation of biological material, methodology of immunohistochemical staining, and interpretation of the results obtained were evaluated. Analytical evaluation was carried out by experts in accordance with the criteria of international standards (CAP, NordiQC). Results. The analysis of the pre-analytical stage revealed methodological inconsistencies related to the processes of fixation of biological material, to the degree of DNA degradation and to the qualitative characteristics of histologic processing. At the analytical stage, the main errors were inadequate selection of antibodies and detection systems, and insufficient validation of diagnostic protocols. The postanalytic phase was characterized by a predominance of factors of incorrect conclusions, including errors in interpretation of HER2 status and molecular genetic subtypes of breast carcinoma. Repeated rounds of follow-up demonstrate that implementation of expert recommendations contributes to statistically significant improvements in diagnostic quality. Conclusion. The system of external quality control of immunohistochemical studies represents a key tool to optimize the accuracy and reproducibility of morphological diagnostics. Systematic participation of laboratories in control programs, standardization of methodological approaches and improvement of professional qualification of specialists ensure minimization of diagnostic errors and increase of clinical significance of research results.


  • Neuroendocrine tumor of the extrahepatic bile ducts. Case report and literature review

    by D.E. Suraev, S.O. Zagagov, N.A. Savelov, A.A. Ajazova, D.YU. Kanner, O.V. Paklina

    Neuroendocrine neoplasms (NENs) are heterogeneous tumors with a common phenotype. There are two fundamentally different groups of NENs: well differentiated with a low proliferative index, called neuroendocrine tumors (NETs) and poorly differentiated with a high proliferative index, called neuroendocrine carcinoma (NEC). Extrahepatic bile duct NETs (EBNETs) account for 0.2% to 2% of all gastrointestinal NETs and up to 2% of all malignant neoplasms of the extrahepatic bile ducts. To date, 114 cases of EBNETs have been described, with disease-free survival ranging from 2 to 240 months. In most cases, the tumors expressed Chromogranin A, Synaptophysin, CD56, and NSE. This report presents a rare case of an EBNET in a 61-year-old patient following resection of the extrahepatic bile ducts. The description includes data from radiological and ultrasound diagnostic methods, macro- and microscopic characteristics of the tumor, and immunohistochemical profile.


  • Open Access

    I St. Petersburg International Consensus on the Diagnosis and Treatment of Breast Cancer «White Nights 2024»

    by Владимир Федорович Семиглазов, Петр Владимирович Криворотько, Татьяна Юрьевна Семиглазова, Елена Владимировна Артамонова, Анна Сергеевна Артемьева, Светлана Геннадьевна Багрова, Лариса Владимировна Болотина, Елена Михайловна Бит-Сава, Алла Александровна Божок, Любовь Юрьевна Владимирова, et al.

    В статье представлены результаты голосования I Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2024», посвященного наиболее актуальным и спорным вопросам диагностики, хирургической тактики, лучевой терапии и системного лечения данной категории пациентов. Под председательством член-корреспондента РАН, профессора Владимира Федоровича Семиглазова в международном консенсусе приняли участие 38 экспертов в области диагностики и лечения рака молочной железы (РМЖ), проголосовавших в ходе прямого эфира по 32 вопросам, разделенным на блоки раннего и метастатического РМЖ. Проведение II Cанкт-Петербургского международного консенсуса по диагностике и лечению РМЖ «Белые ночи 2025» запланировано со 2 по 5 июля 2025 года.


  • Open Access

    Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”

    by Valeriy V. Breder, Liudmila G. Zhukova, Larisa V. Bolotina, Irina A. Demidova, Yaroslav A. Zhulikov, Elena V. Lubennikova, David R. Naskhletashvili, Sergey V. Orlov, Rashida V. Orlova, Ilya S. Romanov, et al.

    NTRK-fusion positive tumors are a rare finding, but targeted therapy demonstrates persistent and sustained systemic and intracranial responses to entrectinib. This resolution proposes algorithms for diagnosing NTRK translocations in various solid tumors and discuses clinical data on the efficacy and safety of entrectinib.


  • Open Access

    Capabilities of Molecular Genetic Methods for Effective Hereditary Cancers Detection in Individuals with High Cancer Risk Factors

    by Анна Борисовна Семенова, Mariya M. Byakhova, Всеволод Николаевич Галкин, Сергей Адольфович Партс, Мария Владимировна Макарова, Marina V. Nemtsova, Denis K. Chernevskiy, Olesya V. Sagaydak, Елена Евгеньевна Баранова, Максим Сергеевич Беленикин, et al.

    Russia and other countries report an increase in the incidence of malignant neoplasms, and approximately 10 % of all oncological cases have hereditary background. Molecular genetic testing in patients with diagnosed malignant neoplasms and a suspected hereditary factor will help to select effective modern methods of treatment and prevention of the development of neoplasms of other localizations. According to the study, 12,6 % of patients had hereditary cancer syndrome, which allowed to administer molecular genetic tests to patients’ relatives. Consequently, it becomes possible to detect hereditary cancer risk factors, improve the efficiency of clinical examination, elaborate and implement programs for prevention and early detection of the disease.